Hep Voice October-December 2025

Welcome to Hep Voice!

As we enter 2026, this edition of Hep Voice captures both the urgency and the opportunities shaping global hepatitis elimination.

Sobering new data on hepatitis C (p.4) reveals how far we still have to go, while debates in the US reflect how misinformation can threaten long-standing progress in hepatitis B vaccination (p.20). Yet, recent updates from Gavi (p.19) also signal important shifts in vaccine access, while the Maldives’ historic achievement as the first country to reach triple mother-to-child transmission elimination (p.4) shows what is possible with strong political will and integrated care.

From peer-led hepatitis C prevention in Ukraine, to Sediba’s integrated care in South Africa (p.22), FUNHEPA’s national movement for liver health in Honduras (p.32), to WHA members’ action during World Hepatitis Testing Week 2025 (p.8), grassroots groups are still reaching communities with testing, awareness, and stories that challenge stigma and drive people toward care.

With the World Hepatitis Summit 2026 approaching, and our NOhep Medical Visionaries programme expanding, WHA is stepping into the new year with determination and clarity of purpose. We know that the tools and knowledge are there for all of us. Now is the time to turn ambition into impact and ensure every community feels the benefits of them.

Happy New Year!  

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close